Arranta Bio adds new manufacturing facility

By The Science Advisory Board staff writers

March 8, 2021 -- Arranta Bio is adding a 130,000-sq-ft facility in Boxborough, MA, to complement its facilities in Watertown, MA, and Gainesville, FL, bringing its total manufacturing capacity to over 130,000 sq ft.

The microbiome contract development and manufacturing organization (CDMO) is developing the Boxborough site in phases, and work on the first two phases has already begun. Construction is underway, and operations of good manufacturing practice (GMP) suites are expected in early 2022. The facility will employ over 150 people and will have a flexible design with dedicated lab and GMP capacity to support commercial products or pipeline products for clients.

Image courtesy of Arranta Bio.
Image courtesy of Arranta Bio.

GMP manufacturing suites will accommodate product-specific processing requirements for both drug substance and finished drug products. Initially, Arranta will provide clients with up to multiple 2,000-L scale single-use bioreactors for anaerobic bacteria or 1,000-L scale single-use fermenters for aerobic bacteria and fully automated drug product manufacturing. The company plans to add secondary packaging and labeling capabilities at the facility.

The total investment in the facility is expected to exceed $150 million. The company announced that it closed an oversubscribed series B equity financing from current investors to fund the expansion.

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter